Trial | NCT00602173  Report issue

Title

Bioequivalency Study of 100 mg Cilostazol Tablets Under Fasting Conditions
A Single Dose, Randomized, Three-Period, Three-Treatment, Crossover Bioequivalency Study of Cilostazol 100 mg Tablets Under Fasting Conditions

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    cilostazol ...

  • Study Participants

    32
The objective of this study was the bioequivalence of a Roxane Laboratories' Cilostazol Tablets, 100 mg, to PLETAL® Tablets, 100 mg (OTSUKA Pharmaceuticals) under fasting conditions using a single-dose, randomized, 3-treatment, 3-period, crossover design.
Study Started
May 31
2003
Primary Completion
May 31
2003
Study Completion
May 31
2003
Last Update
Jan 23
2018

Drug Cilostazol

Criteria 

Inclusion Criteria:

No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.

Exclusion Criteria:

Positive test for HIV, Hepatitis B, or Hepatitis C.
Treatment with known enzyme altering drugs.
History of allergic or adverse response to Cilostazol or any comparable or similar product.
No Results Posted